A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Amydis Inc.
Study ID
NCT06223048
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Primary Open Angle Glaucoma

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • AMDX-2011P — DRUG
    AMDX-2011P single bolus injection intravenous for diagnostic review

Study Details

The purpose of this research study is to assess the ability of AMDX- 2011P to identify amyloid deposits in the retina of participants with Primary Open Angle Glaucoma (POAG).

Key Dates

Start date
Dec 7, 2023
Status verified
Jul 2024
Primary completion
Nov 30, 2024
Completion
Feb 28, 2025

Study Design

Enrollment
50 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • Experimental: AMDX-2011P 50 mg
    AMDX2011P mg 50 (2ml) single bolus injection intravenous for diagnostic review
  • Experimental: AMDX-2011P 100 mg
    AMDX2011P 100mg (4ml) single bolus injection intravenous for diagnostic review

Primary Outcome Measure

AMDX-2011P Adverse Events Profile [ Time Frame: 8 days ]

Central Contacts

Locations (3)

FacilityCityStateZIPSite coordinators
Associated Retina ConsultantsPhoenixArizona85020
Mallory Mintert
[email protected]
Global Research ManagementGlendaleCalifornia91204
Logi El-Harazi
[email protected]
Eye Research FoundationNewport BeachCalifornia92663

Find similar trials in Phoenix, AZ

By research site
Associated Retina Consultants· Phoenix, AZGlobal Research Management· Glendale, CAEye Research Foundation· Newport Beach, CA

Related Studies